BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Interpace Diagnostics to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Business Progress on Monday November 13, 2017

  The live webcast and subsequent replay may be accessed by visiting Interpace’s website www.interpacediagnostics.com.

  November 9, 2017

   · 

  3 min read
• Business

  Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Fourth Quarter Cash Dividend, Sets Fiscal 2018 Cash Dividend Rate, and Reaffirms Fiscal 2018 Guidance

  The company reported fourth quarter and full-year fiscal 2017 net revenues of $49.7 million and $200.8 million.

  November 9, 2017

   · 

  17 min read
• Business

  Onconova Therapeutics Reports Business Highlights and Third Quarter 2017 Financial Results

  Cash, cash equivalents, and marketable securities as of September 30, 2017 totaled $7.6 million, compared to $21.4 million as of December 31, 2016.

  November 9, 2017

   · 

  13 min read
• Drug Development

  RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study With RHB-104 for Crohn’s Disease

  Top-line results are expected to be announced in mid-2018.

  November 9, 2017

   · 

  3 min read
• Drug Development

  Lancet Neurology Publishes Results From CSL Behring Phase III Study of Hizentra to Treat Patients With Chronic Inflammatory Demyelinating Polyneuropathy

  The Hizentra PATH study is the largest controlled clinical study in patients with CIDP.

  November 9, 2017

   · 

  8 min read
• Business

  Prometic to Report its Third Quarter 2017 Financial Results and to Hold Conference Call / Webcast

  Prometic will host a conference call at 11:00am (ET) on Tuesday November 14, 2017.

  November 9, 2017

   · 

  3 min read
• Drug Development

  Myovant Sciences Announces Positive Top-line Results From Takeda’s Phase III Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated With Uterine Fibroids

  Relugolix met the primary endpoint with 57.6% of women achieving marked improvement in pain symptoms compared to 3.1% of women receiving placebo.

  November 9, 2017

   · 

  10 min read
• Policy

  Alkermes Calls for Impartial National Review of Scientific Data Supporting the Use of FDA-Approved Treatment Options for Opioid Dependence

  The goal of this review should be to establish a shared national understanding of the characteristics of these medicines and the scientific and medical evidence supporting their use.

  November 9, 2017

   · 

  4 min read
• Business

  Pivot Pharma Licenses Thrudermic Transdermal Nanotechnology and Expands Scientific Advisory Board

  Pivot Pharma is pleased to announce the signing of a Binding Letter of Intent with Thrudermic, LLC, a privately held North Carolina company, to acquire worldwide rights to Thrudermic’s Transdermal Nanotechnology for the development and commercialization of topical cannabinoids.

  November 9, 2017

   · 

  4 min read
• Business

  PENTAX Medical Announces License Agreement With American Speech-Language-Hearing Association To Digitize Clinical Assessment Tool For Voice Disorders

  The agreement was announced during the ASHA Annual Convention.

  November 9, 2017

   · 

  3 min read